

Special Issue

Immune Responses to Vaccines in Patients with Hematologic Diseases

Message from the Guest Editor

Patients with rare blood cancers (blood neoplasms) faced challenges during the COVID-19 pandemic until active and passive measures were implemented. The severity of the disease is influenced by various factors, such as the patient's immunity and treatment. The safety and efficacy of disease measures may vary depending on the SARS-CoV-2 variant and the disease epidemiology. To address these issues, this Special Issue will gather an important collection of articles that explore the latest research and development efforts in this field. We welcome original articles, reviews, and viewpoints covering vaccines and the experiences of hematologists and infectious disease specialists who have treated blood neoplasm patients with SARS-CoV-2.

Guest Editor

Dr. Monia Marchetti

Hematology Department, University Hospital SS Antonio e Biagio & Cesare Arrigo, Alessandria, Italy

Deadline for manuscript submissions

closed (31 January 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/199720

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).